Triptafen-DA for the patient trapped by depression and anxiety: wren.

Contributors

Allen & Hanburys

Publication/Creation

London: Allen & Hanburys, 1966.

Persistent URL

https://wellcomecollection.org/works/vcq783jr

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection 183 Euston Road London NW1 2BE UK T +44 (0)20 7611 8722 E library@wellcomecollection.org https://wellcomecollection.org



WREN.



Triptafen-DA

for the patient trapped by depression and anxiety

Many emotionally disturbed patients presenting to the General Practitioner exhibit depression and anxiety simultaneously. Treatment of the two symptoms must itself be simultaneous, otherwise alleviation of one may aggravate the other. Triptafen-DA was designed specifically to meet this situation. Triptafen-DA is a balance of two psychotropic agents: perphenazine the tranquilliser and amitriptyline the antidepressant. Both are well established and well documented. Both combine high efficacy with low incidence of side effects.

Triptafen-DA tablets contain amitriptyline HCI 25mg and perphenazine BP 2mg The basic NHS cost of 50 tablets is 13/10d

Full information on request



Allen & Hanburys Limited London E2

"Triptalen-DA" is a registered trade mark

66/250/H

PRINTED IN ENGLAND